Nucleai is a leading provider of an AI-powered precision oncology platform transforming biomarker discovery and treatment decisions.
Nucleai is making biopsy diagnoses accurate, efficient and accessible to improve the current standard of care in the field of oncology and to expedite the development of novel cancer treatments.
Nucleai was founded in 2017 by Avi Veidman, Eliron Amir and Lotan Chorev. The company is headquartered in Tel Aviv, Israel.
Nucleai’s platform has been adapted from technology used to gather intelligence about military targets from geospatial data coming from satellite and high-altitude images, now applied to the mapping of biological microenvironments.
Nucleai is the only company to provide a comprehensive suite of solutions for biopsies relating to gastrointestinal, breast and prostate analysis.
Nucleai works with leading pharmaceutical companies, licensing its research platform for internal use, and collaborating in biomarkers discovery projects.
Nucleai is backed by Sanofi Ventures, Section 32, Vertex Ventures, Debiopharm, Fosun RZ Capital, Grove Ventures, and others. The company raised $33M in a Series B round on Mar 22, 2022. This brings Nucleai's total funding to $46.5M to date.